Clinical guidance for youth with myocarditis and pericarditis following mRNA COVID-19 Vaccination

ASEM 文献综述

Official Canadian Paediatric Society document (2021) on “Clinical guidance for youth with myocarditis and pericarditis following mRNA COVID-19 Vaccination”. This practice point aims to provide clinical guidance on myocarditis and pericarditis following mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna). The benefits of COVID-19 vaccination outweigh the risks, and the vaccine is recommended for all eligible individuals, including children and youth in their 12th year and over. A small increased risk of myocarditis and pericarditis (< 1 case per 10,000) has been repor.

此摘要有助于您识别文档。对于临床建议，请始终查阅官方现行版本及其更新日期。